Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial

Shunsuke Nakakura1, Hitoshi Tabuchi1, Yukio Baba2, Futoshi Maruiwa2, Nobuko Ando2, Takashi Kanamoto3, Yoshiaki Kiuchi31Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo Prefecture, Japan; 2Department of Ophthalmology, Baba Eye Clinic, Hiroshima, Japan, 3Department of Ophthalmol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kanamoto T, Ando N, Maruiwa F, Baba Y, Nakakura S, Tabuchi H, Kiuchi Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e7d0fea4d4f24cc981076c6e4a5a1bc3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e7d0fea4d4f24cc981076c6e4a5a1bc3
record_format	dspace
spelling	oai:doaj.org-article:e7d0fea4d4f24cc981076c6e4a5a1bc32021-12-02T12:01:27ZComparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial1177-54671177-5483https://doaj.org/article/e7d0fea4d4f24cc981076c6e4a5a1bc32012-03-01T00:00:00Zhttp://www.dovepress.com/comparison-of-the-latanoprost-0005timolol-05--brinzolamide-1-versus-do-a9416https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Shunsuke Nakakura1, Hitoshi Tabuchi1, Yukio Baba2, Futoshi Maruiwa2, Nobuko Ando2, Takashi Kanamoto3, Yoshiaki Kiuchi31Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo Prefecture, Japan; 2Department of Ophthalmology, Baba Eye Clinic, Hiroshima, Japan, 3Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima City, JapanObjective: To compare the safety and effectiveness of fixed-combination regimes (latanoprost&ndash;timolol and brinzolamide 1% compared to dorzolamide 1%/timolol and latanoprost) in open-angle glaucoma patients after switching from a combination of three topical antiglaucoma eye drops.Methods: We conducted an open, randomized 12-week multicenter prospective study. We randomly allocated 39 patients who had been treated with three antiglaucoma eye drops (prostaglandin F2&alpha; analogues plus beta-blockers and carbonic anhydrase inhibitors) into two groups. Group A (n = 20) were treated with latanoprost&ndash;timolol and brinzolamide 1% therapy and Group B (n = 16) were treated with dorzolamide 1%/timolol and latanoprost. Thirty-six patients completed all 12 weeks of this study. The major clinical parameters measured were intraocular pressure (IOP), conjunctive hyperemia, superficial punctate keratopathy and hyperpigmentation of eyelid at baseline, 4, and 12 weeks. Additionally noted were adverse events and patient preferences, measured using a questionnaire at study initiation and at 12 weeks.Results: At baseline, IOPs were (Group A: 14.1 &plusmn; 2.9 mmHg, B: 14.5 &plusmn; 2.9 mmHg; P = 0.658), (Group A: 13.8 &plusmn; 2.6 mmHg, B: 14.3 &plusmn; 2.8 mmHg; P = 0.715) at 4 weeks, and (Group A: 14.1 &plusmn; 2.7 mmHg, B: 14.2 &plusmn; 2.7 mmHg; P = 0.538) at 12 weeks. Among the groups, there was no significant difference at any time point after baseline (P = 0.923, 0.951, respectively). All adverse events were not remarkably different after therapy. In regards to patient preference before and after switching therapy, 10 patients (50%) in Group A and 10 patients (63%) in Group B preferred using fixed-combination eye drop therapy.Conclusions: Effectiveness and safety were maintained in both groups after switching therapy. Overall, patients generally preferred using a fixed-combination therapy.Keywords: glaucoma, latanoprost&ndash;timolol, dorzolamide&ndash;timolol, brinzolamide, fixed combination, intraocular pressureKanamoto TAndo NMaruiwa FBaba YNakakura STabuchi HKiuchi YDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 369-375 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Kanamoto T Ando N Maruiwa F Baba Y Nakakura S Tabuchi H Kiuchi Y Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
description	Shunsuke Nakakura1, Hitoshi Tabuchi1, Yukio Baba2, Futoshi Maruiwa2, Nobuko Ando2, Takashi Kanamoto3, Yoshiaki Kiuchi31Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Hyogo Prefecture, Japan; 2Department of Ophthalmology, Baba Eye Clinic, Hiroshima, Japan, 3Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima City, JapanObjective: To compare the safety and effectiveness of fixed-combination regimes (latanoprost&ndash;timolol and brinzolamide 1% compared to dorzolamide 1%/timolol and latanoprost) in open-angle glaucoma patients after switching from a combination of three topical antiglaucoma eye drops.Methods: We conducted an open, randomized 12-week multicenter prospective study. We randomly allocated 39 patients who had been treated with three antiglaucoma eye drops (prostaglandin F2&alpha; analogues plus beta-blockers and carbonic anhydrase inhibitors) into two groups. Group A (n = 20) were treated with latanoprost&ndash;timolol and brinzolamide 1% therapy and Group B (n = 16) were treated with dorzolamide 1%/timolol and latanoprost. Thirty-six patients completed all 12 weeks of this study. The major clinical parameters measured were intraocular pressure (IOP), conjunctive hyperemia, superficial punctate keratopathy and hyperpigmentation of eyelid at baseline, 4, and 12 weeks. Additionally noted were adverse events and patient preferences, measured using a questionnaire at study initiation and at 12 weeks.Results: At baseline, IOPs were (Group A: 14.1 &plusmn; 2.9 mmHg, B: 14.5 &plusmn; 2.9 mmHg; P = 0.658), (Group A: 13.8 &plusmn; 2.6 mmHg, B: 14.3 &plusmn; 2.8 mmHg; P = 0.715) at 4 weeks, and (Group A: 14.1 &plusmn; 2.7 mmHg, B: 14.2 &plusmn; 2.7 mmHg; P = 0.538) at 12 weeks. Among the groups, there was no significant difference at any time point after baseline (P = 0.923, 0.951, respectively). All adverse events were not remarkably different after therapy. In regards to patient preference before and after switching therapy, 10 patients (50%) in Group A and 10 patients (63%) in Group B preferred using fixed-combination eye drop therapy.Conclusions: Effectiveness and safety were maintained in both groups after switching therapy. Overall, patients generally preferred using a fixed-combination therapy.Keywords: glaucoma, latanoprost&ndash;timolol, dorzolamide&ndash;timolol, brinzolamide, fixed combination, intraocular pressure
format	article
author	Kanamoto T Ando N Maruiwa F Baba Y Nakakura S Tabuchi H Kiuchi Y
author_facet	Kanamoto T Ando N Maruiwa F Baba Y Nakakura S Tabuchi H Kiuchi Y
author_sort	Kanamoto T
title	Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
title_short	Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
title_full	Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
title_fullStr	Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
title_full_unstemmed	Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
title_sort	comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/e7d0fea4d4f24cc981076c6e4a5a1bc3
work_keys_str_mv	AT kanamotot comparisonofthelatanoprost0005timolol05brinzolamide1versusdorzolamide1timolol05latanoprost0005a12weekrandomizedopenlabeltrial AT andon comparisonofthelatanoprost0005timolol05brinzolamide1versusdorzolamide1timolol05latanoprost0005a12weekrandomizedopenlabeltrial AT maruiwaf comparisonofthelatanoprost0005timolol05brinzolamide1versusdorzolamide1timolol05latanoprost0005a12weekrandomizedopenlabeltrial AT babay comparisonofthelatanoprost0005timolol05brinzolamide1versusdorzolamide1timolol05latanoprost0005a12weekrandomizedopenlabeltrial AT nakakuras comparisonofthelatanoprost0005timolol05brinzolamide1versusdorzolamide1timolol05latanoprost0005a12weekrandomizedopenlabeltrial AT tabuchih comparisonofthelatanoprost0005timolol05brinzolamide1versusdorzolamide1timolol05latanoprost0005a12weekrandomizedopenlabeltrial AT kiuchiy comparisonofthelatanoprost0005timolol05brinzolamide1versusdorzolamide1timolol05latanoprost0005a12weekrandomizedopenlabeltrial
_version_	1718394781517742080

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial

Ejemplares similares